ADMA Stock Analysis: Buy, Sell, or Hold?
ADMA - ADMA Biologics, Inc.
$9.11
0.10 (1.11%)
▲
5d:
-5.4%
30d:
-44.38%
90d:
-50.38%
HOLD
LOW Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
ADMA is down 5.3% this week, but smart money is accumulating calls. Top strike: $11 2026-05-15 with 10,935 OI. Call ratio: 86% View Scanner →
Strength: 6.3/10
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ADMA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ADMA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$43.80
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$27.20
66.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $9.11, which is considered oversold relative to its 30-day fair value range of $11.23 to $16.76. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.6) compared to its historical average (16.3). Remarkably, the market is currently pricing in an annual earnings decline of 26.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ADMA is in a strong downtrend. Immediate support is located at $7.21, while resistance sits at $15.22.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $23.50 (+158.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ADMA is in a strong downtrend. Immediate support is located at $7.21, while resistance sits at $15.22.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $23.50 (+158.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$11.23 -
$16.76
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding ADMA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 158.0% below Wall St target ($23.50)
- CAUTION: Recommendation downgraded due to -5.4% 5-day decline
Fair Price Analysis
30-Day Fair Range
$11.23 -
$16.76
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$7.21
Resistance Level
$15.23
Current Trend
Strong Downtrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.60
Wall Street Target
$23.50
(+158.0%)
Revenue Growth (YoY)
18.4%
Earnings Growth (YoY)
-52.8%
Profit Margin
28.8%
Valuation Discount vs History
-26.0% cheaper
PE vs Historical
6.6 vs 16.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-26.0%
(market-implied from PE analysis)
1-Year Target
$8.20
(-10%)
2-Year Target
$7.38
(-19%)
3-Year Target
$6.64
(-27%)
3-Yr Target (if PE normalizes)
(PE: 7→16)
$16.40
(+80%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 32.7%)
$72.06
(+691%)
Base:
(SPY PE: 6.6, Growth: 32.7%)
$21.28
(+134%)
Bear:
(PE: 5.6, Growth: 32.7%)
$18.09
(+99%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 23.87 | Current EPS (TTM): $0.60
Bull Case
$31.50
(+132%)
Analyst growth 100.0%, PE expands to 26.3
Base Case
$28.64
(+111%)
Market implied 100.0%, PE stable at 23.9
Bear Case
$9.74
(-28%)
Severe decline -20.0%, PE contracts to 20.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.6 to 16.3
Stabilization Target:
$22.49
(+146.9%)
PE Expansion Potential:
+146.9%
Share & Embed Analysis
Last updated: April 02, 2026 7:55 AM ET
Data refreshes hourly during market hours. Next update: 8:55 AM
Data refreshes hourly during market hours. Next update: 8:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Kaitlin M Kestenberg-Mes…
SELL
10096 shares
2026-03-09
Steve Elms
BUY
7000 shares
2026-03-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 65 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 55 HOLD |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
